FDA approves Itovebi for advanced HR+ve, HER2-neg breast cancer with a PIK3CA mutation October 15, 2024
Enhertu approved in China as first HER2-directed therapy for patients with HER2-mutant metastatic NSCLC October 15, 2024
IV Opdivo Approved in Taiwan in Combination with Cisplatin & Gemcitabine for the 1L Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma October 15, 2024
US FDA Approves Perioperative Treatment of Neoadjuvant Opdivo and Chemo Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable NSCLC October 8, 2024
China NMPA approves Cadonilimab for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population October 8, 2024
EC approved toripalimab (LOQTORZI®) for the treatment of certain patients with mNPC and ESCC October 2, 2024
Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer October 2, 2024
FDA grants full approval to selpercatinib for RET fusion-positive medullary thyroid cancer October 1, 2024
FRUZAQLA (fruquintinib) approved in Japan for the Treatment of Unresectable Advanced or Recurrent CRC October 1, 2024
KEYTRUDA Receives New Approvals in Japan for perioperative Patients With NSCLC and in Radically Unresectable Urothelial Carcinoma October 1, 2024
European Commission approves VYLOY (zolbetuximab) + chemo combo for 1L HER2-neg, CLDN 18.2 +ve gastric/GEJ adenocarcinoma September 25, 2024
RYBREVANT® (amivantamab-vmjw) + SOC approved in the US to cut risk of disease progression by more than half in 2L EGFR-mutated advanced NSCLC September 24, 2024
FDA Approves KEYTRUDA + Pemetrexed + Chemo as 1L Treatment for Adult Patients With Unresectable Advanced/Metastatic Malignant Pleural Mesothelioma (MPM) September 24, 2024
FDA approves Kisqali to reduce risk of recurrence in people with HR+/HER2- early breast cancer September 24, 2024
Sarclisa + SOC approved in the US for adult patients with newly diagnosed multiple myeloma not eligible for transplant September 24, 2024
FDA approves BORUZU, a new presentation of bortezomib for ready-to-use subcutaneous administration or IV administration September 10, 2024
Alecensa Approved in Japan for the Additional Indication of Adjuvant Treatment for People with ALK-Positive Early-Stage NSCLC September 3, 2024
European Commission Approves BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) for the treatment of adult patients with advanced NSCLC with a BRAFV600E mutation September 3, 2024
European Commission approves RYBREVANT (amivantamab) + chemo for adult patients with advanced EGFR-mutated NSCLC after failure of prior therapy September 3, 2024
European Commission Approves PADCEV (enfortumab vedotin) + KEYTRUDA (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer September 3, 2024
RYBREVANT (amivantamab-vmjw) + LAZCLUZE (lazertinib) approved in the U.S. for patients with EGFR-mutated advanced lung cancer August 27, 2024
EU Approves TEPKINLY® (epcoritamab) for the Treatment of Adults with R/R Follicular Lymphoma August 27, 2024
European Commission approves BALVERSA (erdafitinib) for adult patients with unresectable or metastatic urothelial carcinoma August 27, 2024
Lynparza and Imfinzi combination approved in the EU for patients with MMR-proficient advanced or recurrent endometrial cancer August 22, 2024
